Afficher la notice abrégée

The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration

dc.rights.licenseopenen_US
dc.contributor.authorTALKS, J.
dc.contributor.authorDAIEN, V.
dc.contributor.authorFINGER, R. P.
dc.contributor.authorELDEM, B.
dc.contributor.authorSAKAMOTO, T.
dc.contributor.authorCARDILLO, J. A.
dc.contributor.authorMITCHELL, P.
dc.contributor.authorWONG, T. Y.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.date.accessioned2020-07-15T07:45:41Z
dc.date.available2020-07-15T07:45:41Z
dc.date.issued2019-09
dc.identifier.issn1879-3304 (Electronic) 0039-6257 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10467
dc.description.abstractEnRandomized controlled trials are the gold standard in medical research, providing evidence of the efficacy of a treatment in well-defined patient populations. By contrast, real-world studies explore the effectiveness of treatments in routine clinical practices, often with diverse patient populations. While both randomized controlled trials and real-world studies contribute to the understanding of the benefits and risks of therapies, they generate different types of data and serve complementary purposes. Real-world studies evaluating the management of neovascular age-related macular degeneration (nAMD) have shown that visual outcomes achieved with anti-vascular endothelial growth factor (VEGF) in clinical practice often differ from those derived from clinical trials, highlighting the importance of assessing such outcomes in real world studies. Benefits have included finding variations in treatment provision leading to service improvements, the understanding of the need for continued and higher than previously provided treatment frequency, and new treatment regimens such as treat and extend. There is potential for the scope of real-world studies to be expanded to include other patient outcomes, such as on quality of life, thus providing decision-makers with additional information to complement the data collected in randomized controlled trials. Physicians, patients, and regulators stand to gain much from further development and conduct of real-world studies. We provide an overview of the importance of real-world evidence in the management of nAMD with anti-VEGF therapy, describes sources of real-world evidence, and assesses the relative strengths and limitations of randomized controlled trials and real-world studies.
dc.language.isoENen_US
dc.subject.enLEHA
dc.title.enThe use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration
dc.title.alternativeSurv Ophthalmolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.survophthal.2019.02.008en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30797883en_US
bordeaux.journalSurvey of ophthalmologyen_US
bordeaux.page707-719en_US
bordeaux.volume64en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue5en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Survey%20of%20ophthalmology&rft.date=2019-09&rft.volume=64&rft.issue=5&rft.spage=707-719&rft.epage=707-719&rft.eissn=1879-3304%20(Electronic)%200039-6257%20(Linking)&rft.issn=1879-3304%20(Electronic)%200039-6257%20(Linking)&rft.au=TALKS,%20J.&DAIEN,%20V.&FINGER,%20R.%20P.&ELDEM,%20B.&SAKAMOTO,%20T.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée